GlassScriptPhysician profile
Amy T Tran
NPI 1275876260
$3,913.07
in general payments reported to CMS, 2019-2025
23 companies · $2,012 in 2025
The $2,012 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $23.45 · 2023: $173 · 2024: $1,704 · 2025: $2,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,889.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $399.98 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $385.56 | 2023-2025 | Zepbound, Jardiance, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $382.10 | 2024-2025 | Rexulti |
| Abbvie INC. | $317.56 | 2023-2025 | |
| Amgen INC. | $303.58 | 2023-2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $298.18 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $278.11 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $246.86 | 2024-2025 | |
| Pfizer INC. | $227.43 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $177.35 | 2024-2025 | Xifaxan |
| Exact Sciences Corporation | $149.17 | 2024-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $141.17 | 2024-2025 | |
| Paratek Pharmaceuticals, INC. | $123.19 | 2024-2025 | Nuzyra, Xhance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.04 | 2024-2025 | Jardiance |
| Astellas Pharma US INC | $78.07 | 2024 | Veozah |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $68.25 | 2025 | Freestyle Libre 3 |
| Dexcom, INC. | $63.17 | 2024-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $60.44 | 2023-2024 | Spravato |
| Dynavax Technologies Corporation | $42.44 | 2023-2025 | Heplisav-B |
| Sumitomo Pharma America, INC. | $37.57 | 2025 | Gemtesa |
| Kerecis Limited | $15.71 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Kowa Pharmaceuticals America, INC. | $15.11 | 2025 | Zoryve |
| Tolmar, INC. | $14.03 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.